AR030609A1 - Composicion catartica - Google Patents
Composicion catarticaInfo
- Publication number
- AR030609A1 AR030609A1 ARP010104216A ARP010104216A AR030609A1 AR 030609 A1 AR030609 A1 AR 030609A1 AR P010104216 A ARP010104216 A AR P010104216A AR P010104216 A ARP010104216 A AR P010104216A AR 030609 A1 AR030609 A1 AR 030609A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- catartic
- constipation
- halogenated
- bicyclic compound
- Prior art date
Links
- 206010010774 Constipation Diseases 0.000 abstract 2
- -1 halogenated bicyclic compound Chemical class 0.000 abstract 2
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Abstract
Un objeto de la presente invencion consiste en proveer una composicion contra la constipacion que contenga un compuesto bicíclico halogenado como ingrediente activo en una relacion de estructura bicíclica/monocíclica de al menos 1 : 1. El compuesto bicíclico halogenado se representa por medio de la formula (1) donde X1 y X2 son preferentemente átomos de fluor. La composicion puede utilizarse para tratar la constipacion sin importantes efectos colaterales, tales como dolor de estomago.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/655,760 US6414016B1 (en) | 2000-09-05 | 2000-09-05 | Anti-constipation composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030609A1 true AR030609A1 (es) | 2003-08-27 |
Family
ID=24630250
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010104216A AR030609A1 (es) | 2000-09-05 | 2001-09-05 | Composicion catartica |
ARP130103006A AR100291A2 (es) | 2000-09-05 | 2013-08-26 | Composición catártica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103006A AR100291A2 (es) | 2000-09-05 | 2013-08-26 | Composición catártica |
Country Status (25)
Country | Link |
---|---|
US (7) | US6414016B1 (es) |
EP (2) | EP1857105B1 (es) |
JP (3) | JP2004508327A (es) |
KR (2) | KR100918223B1 (es) |
CN (1) | CN100335049C (es) |
AR (2) | AR030609A1 (es) |
AT (1) | ATE476975T1 (es) |
AU (2) | AU2001282615B2 (es) |
BR (1) | BRPI0114042B8 (es) |
CA (1) | CA2419741C (es) |
CZ (1) | CZ304740B6 (es) |
DE (2) | DE60131547T2 (es) |
DK (2) | DK1315485T3 (es) |
ES (2) | ES2347697T3 (es) |
HU (1) | HU229319B1 (es) |
IL (2) | IL154534A0 (es) |
MX (1) | MXPA03001959A (es) |
NL (1) | NL300757I2 (es) |
NO (1) | NO332701B1 (es) |
NZ (1) | NZ524401A (es) |
PT (2) | PT1857105E (es) |
RU (1) | RU2694361C3 (es) |
TW (1) | TWI305147B (es) |
WO (1) | WO2002020007A1 (es) |
ZA (1) | ZA200301673B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ303625B6 (cs) * | 1999-10-15 | 2013-01-16 | Sucampo Ag | Stabilní farmaceutický prostredek obsahující bicyklickou slouceninu a acyglycerol, bicyklická sloucenina, zpusob stabilizace bicyklické slouceniny, farmaceutický prostredek obsahující bicyklickou slouceninu |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
AR037524A1 (es) * | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
PT1562604E (pt) * | 2002-10-23 | 2012-04-09 | Sucampo Ag | Compostos de prostaglandina para o tratamento de obesidade |
CA2510051C (en) * | 2002-12-27 | 2016-07-05 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
DE602004030245D1 (de) * | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
TWI348386B (en) * | 2003-08-12 | 2011-09-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
RU2440338C2 (ru) | 2005-01-27 | 2012-01-20 | Сукампо Аг | Способ и композиция для лечения заболеваний центральной нервной системы |
KR20140098857A (ko) | 2005-03-04 | 2014-08-08 | 수캄포 아게 | 말초 혈관 질환 치료를 위한 방법 및 조성물 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
EP1871380B1 (en) * | 2005-04-12 | 2011-10-19 | Sucampo AG | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
BRPI0707333B8 (pt) * | 2006-01-24 | 2021-05-25 | R Tech Ueno Ltd | composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole |
CN103804338A (zh) * | 2006-02-07 | 2014-05-21 | 株式会社·R-技术上野 | 用于制备前列腺素衍生物的方法 |
US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
US20090030072A1 (en) * | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
CN101318948B (zh) * | 2008-04-01 | 2011-04-27 | 上海天伟生物制药有限公司 | 鲁比前列酮晶体、其制备方法及用途 |
US8513441B2 (en) * | 2008-08-29 | 2013-08-20 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
CN102245176B (zh) * | 2008-10-31 | 2015-05-27 | 脂质医药有限公司 | 用作药物的脂肪酸 |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
MX345283B (es) | 2008-12-31 | 2017-01-24 | Ardelyx Inc | Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal. |
US9382272B2 (en) | 2009-01-22 | 2016-07-05 | Apotex Pharmachem Inc. | Methods of making lubiprostone and intermediates thereof |
US9084815B2 (en) * | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
TW201118084A (en) * | 2009-09-18 | 2011-06-01 | Adolor Corp | The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders |
US8940790B2 (en) * | 2009-11-03 | 2015-01-27 | Bernard Charles Sherman | Stable pharmaceutical formulations comprising lubiprostone |
WO2011072383A1 (en) * | 2009-12-18 | 2011-06-23 | Apotex Pharmachem Inc. | Processes for the purification of lubiprostone |
CA2788334A1 (en) | 2010-01-28 | 2011-08-04 | Apotex Pharmachem Inc. | Polymorphic forms of lubiprostone |
MX366293B (es) | 2012-08-21 | 2019-07-04 | Ardelyx Inc | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
JP6377132B2 (ja) | 2013-04-12 | 2018-08-22 | アーデリクス,インコーポレーテッド | Nhe3結合化合物およびリン酸輸送の阻害方法 |
WO2016161085A1 (en) | 2015-04-01 | 2016-10-06 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
WO2016203317A1 (en) * | 2015-06-19 | 2016-12-22 | Sucampo Ag | Pharmaceutical compositions comprising fatty acid derivative |
JP6957610B2 (ja) | 2016-10-06 | 2021-11-02 | スキャンポ・アーゲーSucampo AG | 医薬品用途のための多層ビーズ |
EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
EP3565808A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
JP6750733B2 (ja) * | 2017-04-20 | 2020-09-02 | 株式会社島津製作所 | 分光光度計 |
US10422729B1 (en) | 2019-03-08 | 2019-09-24 | Biodesix, Inc. | Blood sample separation devices and methods |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5720305B2 (es) | 1973-02-28 | 1982-04-27 | ||
US4034003A (en) | 1974-04-11 | 1977-07-05 | Ono Pharmaceutical Co., Ltd. | 15-Cycloalkyl-prostaglandins |
JPS5350141A (en) | 1976-10-18 | 1978-05-08 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin and prostaglandin analogues |
JPS5391110A (en) | 1977-01-20 | 1978-08-10 | Yamanouchi Pharmaceut Co Ltd | Novel drug composition for rectal infusion |
JPS6022708B2 (ja) | 1977-07-14 | 1985-06-03 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
US4308595A (en) * | 1979-12-19 | 1981-12-29 | International Business Machines Corporation | Array driver |
US4670569A (en) | 1981-04-02 | 1987-06-02 | G. D. Searle & Co. | 5-fluoro-PGI2 compounds |
US4687864A (en) | 1983-12-23 | 1987-08-18 | G. D. Searle & Co. | 5-fluoro-3-oxa-prostacyclin compounds |
US4579958A (en) | 1983-12-23 | 1986-04-01 | G. D. Searle & Co. | 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
DE3873007T2 (de) | 1987-10-02 | 1992-12-03 | Ueno Seiyaku Oyo Kenkyujo Kk | Kathartica. |
JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体 |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
CA2030346C (en) * | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
JP2515442B2 (ja) * | 1990-05-01 | 1996-07-10 | 株式会社上野製薬応用研究所 | 膵臓疾患処置剤 |
CA2041417C (en) * | 1990-05-01 | 2002-05-21 | Ryuji Ueno | Treatment of pancreatic disease with 15-keto-prostaglandin compounds |
JP2938579B2 (ja) | 1990-12-15 | 1999-08-23 | 株式会社上野製薬応用研究所 | 消化管壁保護剤 |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
US5958876A (en) | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
AUPO665397A0 (en) * | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
WO1999045934A1 (fr) | 1998-03-11 | 1999-09-16 | Grelan Pharmaceutical Co., Ltd. | Preparations entero-solubles effervescentes |
US6471085B1 (en) | 1999-10-04 | 2002-10-29 | Anthony J. Gallo | Temperature cup |
CZ303625B6 (cs) * | 1999-10-15 | 2013-01-16 | Sucampo Ag | Stabilní farmaceutický prostredek obsahující bicyklickou slouceninu a acyglycerol, bicyklická sloucenina, zpusob stabilizace bicyklické slouceniny, farmaceutický prostredek obsahující bicyklickou slouceninu |
ES2279467T3 (es) * | 2000-07-14 | 2007-08-16 | Henkel Kommanditgesellschaft Auf Aktien | Solido ahuecado compartimentado que contiene una porcion de detergente, producto de limpieza o aclarador. |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
-
2000
- 2000-09-05 US US09/655,760 patent/US6414016B1/en not_active Expired - Lifetime
-
2001
- 2001-09-04 PT PT07016834T patent/PT1857105E/pt unknown
- 2001-09-04 HU HU0302422A patent/HU229319B1/hu unknown
- 2001-09-04 AT AT07016834T patent/ATE476975T1/de active
- 2001-09-04 AU AU2001282615A patent/AU2001282615B2/en not_active Expired
- 2001-09-04 DK DK01961333T patent/DK1315485T3/da active
- 2001-09-04 DK DK07016834.9T patent/DK1857105T3/da active
- 2001-09-04 DE DE60131547T patent/DE60131547T2/de not_active Expired - Lifetime
- 2001-09-04 MX MXPA03001959A patent/MXPA03001959A/es active IP Right Grant
- 2001-09-04 JP JP2002524492A patent/JP2004508327A/ja active Pending
- 2001-09-04 DE DE60142810T patent/DE60142810D1/de not_active Expired - Lifetime
- 2001-09-04 CZ CZ2003-787A patent/CZ304740B6/cs not_active IP Right Cessation
- 2001-09-04 EP EP07016834A patent/EP1857105B1/en not_active Expired - Lifetime
- 2001-09-04 BR BRPI0114042A patent/BRPI0114042B8/pt not_active IP Right Cessation
- 2001-09-04 TW TW090121835A patent/TWI305147B/zh not_active IP Right Cessation
- 2001-09-04 CN CNB018183239A patent/CN100335049C/zh not_active Ceased
- 2001-09-04 WO PCT/JP2001/007628 patent/WO2002020007A1/en active IP Right Grant
- 2001-09-04 EP EP01961333A patent/EP1315485B1/en not_active Expired - Lifetime
- 2001-09-04 PT PT01961333T patent/PT1315485E/pt unknown
- 2001-09-04 ES ES07016834T patent/ES2347697T3/es not_active Expired - Lifetime
- 2001-09-04 RU RU2003109622A patent/RU2694361C3/ru active Protection Beyond IP Right Term
- 2001-09-04 IL IL15453401A patent/IL154534A0/xx unknown
- 2001-09-04 KR KR1020087021218A patent/KR100918223B1/ko active Protection Beyond IP Right Term
- 2001-09-04 KR KR1020037003261A patent/KR100901102B1/ko active Protection Beyond IP Right Term
- 2001-09-04 ES ES01961333T patent/ES2296786T3/es not_active Expired - Lifetime
- 2001-09-04 AU AU8261501A patent/AU8261501A/xx active Pending
- 2001-09-04 CA CA2419741A patent/CA2419741C/en not_active Expired - Lifetime
- 2001-09-04 NZ NZ524401A patent/NZ524401A/en not_active IP Right Cessation
- 2001-09-05 AR ARP010104216A patent/AR030609A1/es unknown
-
2002
- 2002-05-06 US US10/138,650 patent/US6610732B2/en not_active Expired - Fee Related
-
2003
- 2003-02-19 IL IL154534A patent/IL154534A/en not_active IP Right Cessation
- 2003-02-28 ZA ZA200301673A patent/ZA200301673B/xx unknown
- 2003-03-04 NO NO20030996A patent/NO332701B1/no not_active IP Right Cessation
- 2003-05-22 US US10/443,046 patent/US20030216465A1/en not_active Abandoned
-
2005
- 2005-06-02 US US11/142,251 patent/US8071613B2/en not_active Expired - Fee Related
-
2009
- 2009-03-04 JP JP2009050902A patent/JP4684334B2/ja not_active Expired - Fee Related
- 2009-09-15 JP JP2009213058A patent/JP2009286806A/ja active Pending
-
2011
- 2011-10-17 US US13/274,612 patent/US8114890B1/en not_active Expired - Lifetime
- 2011-12-27 US US13/337,488 patent/US8748454B2/en not_active Expired - Fee Related
-
2013
- 2013-08-26 AR ARP130103006A patent/AR100291A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/265,467 patent/US20140235665A1/en not_active Abandoned
-
2015
- 2015-08-28 NL NL300757C patent/NL300757I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030609A1 (es) | Composicion catartica | |
ES2191977T3 (es) | Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. | |
AR029462A1 (es) | Derivados del acido picolinico, procedimiento para prepararlos y composiciones formuladas con dichos derivados como agente activo, procedimientos preventivos o curativos contra hongos fitopatogenos, metodos preventivos o de tratamiento de la madera para la construccion utilizando dichos compuestos y | |
UA85660C2 (en) | Azaindoles | |
SV2002000615A (es) | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento ref.pc9923/7000000/bb | |
ES2091441T3 (es) | Composicion farmaceutica. | |
AR019147A1 (es) | Una formulacion de jarabe que contiene antihistaminico | |
MX2007010881A (es) | Composiciones de peroxido de benzoilo y metodos de uso. | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
AR109263A2 (es) | Composición que comprende moxidectina | |
ES2172915T3 (es) | Formulaciones bucodentales que contienen nanofibrillas de celulosa esencialmente amorfas. | |
ATE370730T1 (de) | Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung | |
MX9401009A (es) | Germicida biodegradable hipocompatible, no toxico. | |
HN2001000225A (es) | Composicion blanqueante dental y procedimiento que emplea un agente blanqueante acido dicarboxilico | |
MX9400801A (es) | Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon. | |
ES2098961T3 (es) | Mezcla ultrasuave de tensioactivos. | |
AR018607A1 (es) | Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion | |
ES2108130T3 (es) | Formulaciones farmacologicas mejoradas. | |
EP1341535A4 (en) | SKIN WHITENING AGENT CONTAINING HYDROXYTETRONIC ACID | |
BRPI0411218A (pt) | formulações alvejantes fluorescentes estáveis em estocagem | |
GT199900193A (es) | Combinaciones fungicidas que comprenden tieno [2,3-d] pirimidin-4-ona. | |
CO5011059A1 (es) | Antibioticos de quinolona magnesica | |
AR026911A1 (es) | Preparado farmaceutica para el tratamiento de afecciones tumorales | |
GT200200044A (es) | Compuestos farmaceuticamente activos | |
ES2113533T3 (es) | Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal. |